Addrenex Seals Licensing Agreement With Dream Pharma

Addrenex has formed a partnership with Dream Pharma to advance the treatment of adrenergic-related conditions worldwide. Addrenex has licensed the right to manufacture, market and sell its lead product Clonicel in Korea, to Dream Pharma.

Clonicel is being developed for both the treatment of hypertension and attention deficit hyperactivity disorder. Clonicel is a patented extended-release formulation of clonidine hydrochloride, a drug currently approved for hypertension.

Reportedly, the company will continue to focus on developing treatments for the origin of a range of conditions regulated by the adrenergic system. These conditions range from menopausal flushing to insomnia to pain. Currently, these conditions are being managed symptomatically rather than addressing the root cause.

Steve Butts, vice president, Commercial Operations at Addrenex, said: We are very excited to partner with Dream Pharma to bring this important treatment to children struggling with ADHD in Korea. This agreement is another important milestone for Addrenex as we continue to expand our business activities globally.